This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis

Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) is a rare autoimmune disease, with high mortality in the absence of treatment (1)

  • the role of the anaphylatoxin C5a in AAV has been demonstrated in mice
  • C5a is a C5 cleavage product with chemoattracting activity on immune cells through the stimulation of the C5a receptor (C5aR1)
    • targeting C5aR may reduce AAV-induced lesions by inhibiting the recruitment of inflammatory cells to the active site of vasculitis
    • the C5aR1 inhibitor avacopan has been developed for the treatment of AAV
    • avacopan plus rituximab leads to a high rate of AAV remission and allows forgoing of glucocorticoids (1)

NICE state:

  • Avacopan with a cyclophosphamide or rituximab regimen is recommended, within its marketing authorisation, as an option for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis in adults. It is recommended only if the company provides it according to the commercial arrangement

The NICE committee noted that "...Standard care for granulomatosis with polyangiitis or microscopic polyangiitis usually starts with cyclophosphamide or rituximab, followed by maintenance treatment, usually with azathioprine or rituximab. Corticosteroids are also used throughout treatment. Avacopan is an option to be used alongside this standard care...Evidence from a clinical trial shows that, after a year, avacopan with standard care is more effective at stopping the conditions getting worse than standard care alone. It also suggests that using avacopan with standard care results in less toxicity from corticosteroids, possibly because of less use overall..."

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.